The relationship between metastatic potential and in vitro mechanical properties of osteosarcoma cells.


Journal

Molecular biology of the cell
ISSN: 1939-4586
Titre abrégé: Mol Biol Cell
Pays: United States
ID NLM: 9201390

Informations de publication

Date de publication:
21 03 2019
Historique:
pubmed: 21 2 2019
medline: 11 9 2019
entrez: 21 2 2019
Statut: ppublish

Résumé

Osteosarcoma is the most frequent primary tumor of bone and is characterized by its high tendency to metastasize in lungs. Although treatment in cases of early diagnosis results in a 5-yr survival rate of nearly 60%, the prognosis for patients with secondary lesions at diagnosis is poor, and their 5-yr survival rate remains below 30%. In the present work, we have used a number of analytical methods to investigate the impact of increased metastatic potential on the biophysical properties and force generation of osteosarcoma cells. With that aim, we used two paired osteosarcoma cell lines, with each one comprising a parental line with low metastatic potential and its experimentally selected, highly metastatic form. Mechanical characterization was performed by means of atomic force microscopy, tensile biaxial deformation, and real-time deformability, and cell traction was measured using two-dimensional and micropost-based traction force microscopy. Our results reveal that the low metastatic osteosarcoma cells display larger spreading sizes and generate higher forces than the experimentally selected, highly malignant variants. In turn, the outcome of cell stiffness measurements strongly depends on the method used and the state of the probed cell, indicating that only a set of phenotyping methods provides the full picture of cell mechanics.

Identifiants

pubmed: 30785850
doi: 10.1091/mbc.E18-08-0545
pmc: PMC6589788
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

887-898

Références

Eur Biophys J. 1999;28(4):312-6
pubmed: 10394623
Clin Exp Metastasis. 1999;17(6):501-6
pubmed: 10763916
Cancer Res. 2000 May 1;60(9):2541-6
pubmed: 10811137
Biophys J. 2001 Apr;80(4):1744-57
pubmed: 11259288
Nature. 1975 May 15;255(5505):197-200
pubmed: 1143315
Clin Exp Metastasis. 2002;19(6):477-85
pubmed: 12405284
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
Biophys J. 2005 May;88(5):3689-98
pubmed: 15722433
Lancet Oncol. 2005 Oct;6(10):798-808
pubmed: 16198986
Br J Dermatol. 2006 May;154 Suppl 1:11-5
pubmed: 16712711
Curr Biol. 2006 Aug 8;16(15):1515-23
pubmed: 16890527
Biochim Biophys Acta. 2007 May;1773(5):675-86
pubmed: 17050008
Orphanet J Rare Dis. 2007 Jan 23;2:6
pubmed: 17244349
Acta Biomater. 2007 Jul;3(4):413-38
pubmed: 17540628
Methods Cell Biol. 2007;83:269-94
pubmed: 17613312
Proc Natl Acad Sci U S A. 2007 Oct 2;104(40):15619-24
pubmed: 17893336
Eur J Cell Biol. 2008 Sep;87(8-9):669-76
pubmed: 18295931
Mol Cancer Res. 2008 Sep;6(9):1410-20
pubmed: 18819929
Nat Rev Cancer. 2009 Feb;9(2):108-22
pubmed: 19165226
Biomed Microdevices. 2011 Apr;13(2):291-301
pubmed: 21120698
Phys Biol. 2011 Feb;8(1):015015
pubmed: 21301068
Phys Biol. 2011 Feb;8(1):015009
pubmed: 21301071
Cancer Res. 2011 Aug 1;71(15):5075-80
pubmed: 21642375
Nat Rev Cancer. 2011 Jun 24;11(7):512-22
pubmed: 21701513
Integr Biol (Camb). 2011 Sep;3(9):910-21
pubmed: 21842067
Nature. 2012 Jan 18;481(7381):306-13
pubmed: 22258609
PLoS One. 2012;7(2):e32572
pubmed: 22389710
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Front Oncol. 2012 Sep 18;2:111
pubmed: 23024961
Nat Nanotechnol. 2012 Nov;7(11):757-65
pubmed: 23085644
Sarcoma. 2012;2012:937506
pubmed: 23213280
Cytoskeleton (Hoboken). 2013 Apr;70(4):201-14
pubmed: 23444002
Exp Cell Res. 2013 Oct 1;319(16):2396-408
pubmed: 23806281
Source Code Biol Med. 2013 Aug 09;8(1):16
pubmed: 23938087
Integr Biol (Camb). 2013 Oct;5(10):1262-71
pubmed: 23995847
Nature. 2013 Sep 19;501(7467):365-72
pubmed: 24048069
J Cell Biol. 2014 Mar 3;204(5):669-82
pubmed: 24567359
Nat Methods. 2015 Mar;12(3):199-202, 4 p following 202
pubmed: 25643151
PLoS One. 2015 May 19;10(5):e0125611
pubmed: 25992885
Oncotarget. 2015 Oct 6;6(30):29469-81
pubmed: 26320182
Biophys J. 2015 Nov 17;109(10):2023-36
pubmed: 26588562
J Vis Exp. 2015 Nov 17;(105):
pubmed: 26650118
Nature. 2016 Jan 21;529(7586):298-306
pubmed: 26791720
ACS Nano. 2016 Mar 22;10(3):3365-74
pubmed: 26901115
Nat Methods. 2016 Apr 28;13(5):415-23
pubmed: 27123817
Sci Rep. 2017 Feb 06;7:41633
pubmed: 28164999
Nat Cell Biol. 2017 Jul;19(7):742-751
pubmed: 28628082
Cancer Res. 2017 Sep 1;77(17):4556-4561
pubmed: 28811330
Mol Biol Cell. 2017 Nov 7;28(23):3333-3348
pubmed: 28931598
Cancer Discov. 2017 Nov;7(11):1224-1237
pubmed: 29038232
Methods Mol Biol. 2018;1678:347-369
pubmed: 29071686
Cancer Discov. 2018 Mar;8(3):304-319
pubmed: 29196464
Nat Methods. 2018 Jul;15(7):491-498
pubmed: 29915189
Mol Biol Cell. 2018 Oct 15;29(21):2528-2539
pubmed: 30113874
Int J Dev Biol. 2019;63(1-2):1-8
pubmed: 30919911
Cancer Res. 1988 Sep 15;48(18):5124-8
pubmed: 3409238
Science. 1976 Oct 1;194(4260):23-8
pubmed: 959840

Auteurs

Claude N Holenstein (CN)

Biomechanics Laboratory, University Hospital Balgrist, University of Zürich, 8008 Zürich, Switzerland.
Institute for Biomechanics, ETH Zurich, 8008 Zürich, Switzerland.

Aron Horvath (A)

Biomechanics Laboratory, University Hospital Balgrist, University of Zürich, 8008 Zürich, Switzerland.
Institute for Biomechanics, ETH Zurich, 8008 Zürich, Switzerland.

Barbara Schär (B)

Biomechanics Laboratory, University Hospital Balgrist, University of Zürich, 8008 Zürich, Switzerland.
Institute for Biomechanics, ETH Zurich, 8008 Zürich, Switzerland.

Angelina D Schoenenberger (AD)

Biomechanics Laboratory, University Hospital Balgrist, University of Zürich, 8008 Zürich, Switzerland.
Institute for Biomechanics, ETH Zurich, 8008 Zürich, Switzerland.

Maja Bollhalder (M)

Biomechanics Laboratory, University Hospital Balgrist, University of Zürich, 8008 Zürich, Switzerland.
Institute for Biomechanics, ETH Zurich, 8008 Zürich, Switzerland.

Nils Goedecke (N)

Institute for Biomechanics, ETH Zurich, 8008 Zürich, Switzerland.

Guido Bartalena (G)

Institute for Biomechanics, ETH Zurich, 8008 Zürich, Switzerland.

Oliver Otto (O)

Biotechnology Center, Technische Universität Dresden, 01307 Dresden, Germany.
Zentrum für Innovationskompetenz, Universität Greifswald, 17489 Greifswald, Germany.

Maik Herbig (M)

Biotechnology Center, Technische Universität Dresden, 01307 Dresden, Germany.

Jochen Guck (J)

Biotechnology Center, Technische Universität Dresden, 01307 Dresden, Germany.

Daniel A Müller (DA)

Biomechanics Laboratory, University Hospital Balgrist, University of Zürich, 8008 Zürich, Switzerland.

Jess G Snedeker (JG)

Biomechanics Laboratory, University Hospital Balgrist, University of Zürich, 8008 Zürich, Switzerland.
Institute for Biomechanics, ETH Zurich, 8008 Zürich, Switzerland.

Unai Silvan (U)

Biomechanics Laboratory, University Hospital Balgrist, University of Zürich, 8008 Zürich, Switzerland.
Institute for Biomechanics, ETH Zurich, 8008 Zürich, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH